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Objectives: Epidermicin is a novel antimicrobial peptide that has potent activity against Gram-positive pathogens,
including methicillin-resistant Staphylococcus aureus, and it may have potential for use in therapy for infections
caused by these bacteria, though in vivo efficacy needsto be demonstrated. Galleria mellonella larvae have recently
been introduced as an alternative in vivo model to mammalian systems and here we examined the ability of a syn-
thetic version of epidermicin to protect G. mellonella larvae from infection with S. aureus strains.
Methods: G. mellonella larvae were infected with 2.5×106 cells per larva and then treated with vancomycin or
epidermicin and survival recorded over a 120 h period. Vancomycin was used at up to 50 mg/kg and epidermicin
at up to 200 mg/kg with administration of treatments occurring 0–2 h post-infection.
Results: Epidermicin was shown to be non-toxic and did not stimulate the G. mellonella immune system. When
administered 2 h post-infection at a maximum dose of 200 mg/kg, epidermicin significantly increased survival
in larvae; however, altering the dosage regimen by reducing the time to administration to 30 min post-infection
increased the potency of the peptide.
Conclusions: This is the first report of antimicrobial activity of an artificially synthesized peptide from the type IIc
bacteriocin family. The novel peptide protects G. mellonella larvae from infection with both methicillin-susceptible
and -resistant S. aureus, although the pharmacodynamic properties are not yet optimal.
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Introduction
Currently there is an urgent need to identifyand develop novel anti-
biotics to combat infections caused by drug-resistant bacterial
pathogens. Epidermicin NI01, an unmodified bacteriocin produced
by Staphylococcus epidermidis strain 224, exhibits potent anti-
microbial activity towards a wide range of pathogenic Gram-
positive bacteria, including methicillin-resistant Staphylococcus
aureus (MRSA), vancomycin-resistant enterococci and biofilm-
forming S. epidermidis strains.1 Epidermicin is a member of a
recently described family of type IIc bacteriocins. The activity of
synthetic peptides from this family has not been investigated.
The recent introduction of Galleria mellonella larvae as a model
host provides an alternative in vivo model to mammalian systems.
It fulfils many of the basic requirements of a useful animal model,
most notably the immune system shares a high degree of struc-
tural and functional similarity with that of mammals2 and involves
both cellular and humoral defences. The humoral response
consists of melanization, haemolymph clotting and production
of antimicrobial peptides, whereas the cellular responses consist
of phagocytosis, nodulization and encapsulation. In addition,
G. mellonella has a short life cycle and the larvae are easy to
breed, inexpensive and widely available. Tests using larvae as an
in vivo model are considered simple to initiate, predictable, repro-
ducible and quantifiable, making it a desirable first line of in vivo
testing.3 Larvae of G. mellonella have been used previously as a
model host for studying the virulence of pathogenic microbes, in-
cluding S. aureus,4 Streptococcus species,5,6 P. aeruginosa,7 Bacillus
cereus,8 dermatophytes,9 Aspergillus species,10 Cryptococcus neo-
formans and Candida albicans.11 The larvae have also been used to
study the efficacy of various antimicrobial agents.4
The main objective of this study was to evaluate the anti-
microbial activity of a synthetic epidermicin NI01 peptide
against S. aureus using the wax moth larva G. mellonella as
a model host and to compare the activity with the effect of
vancomycin.
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Materials and methods
Bacterial strain
Methicillin-susceptible S. aureus (MSSA) strain ATCC 11195 and a clinical
isolate of MRSA were employed during the course of this study. The MRSA
strain had been previously collected by staff at a hospital bacteriology la-
boratory in Manchester, UK, and is part of a local culture collection. The
strains were routinely cultured in LB broth (10 g/L tryptone and 5 g/L
yeast extract, with no salt) or Columbia Blood Agar (CBA; Oxoid, UK) incu-
bated at 378C.
Insect larvae
Sixth instar larvae of G. mellonella were obtained from Live Foods Ltd (Rooks
Bridge, UK). Larvae were stored in the dark at 48Cand used within 2 weeks of
receipt.
A Hamilton syringe (26S gauge, 50 mL capacity) was used to inoculate
larvae with S. aureus and for introduction of treatments or control solutions
into the larvae. The methods of Desbois and Coote4 were followed.
Antimicrobial agents
Epidermicin was obtained from Almac Sciences (East Lothian, UK). As the
native peptide is N-formylated, and such modifications are conserved in
bacteriocins, the peptide used in this study was synthesized with this modi-
fication. As the peptide adheres to polystyrene 96-well microtitre plates, the
peptide was dissolved in peptide suspension buffer (0.01% acetic acid
buffercontaining 0.2% BSA)and kept at2208C until required for use. Vanco-
mycin hydrochloride was obtained from Sigma-Aldrich Ltd (Poole, UK) and
was prepared using sterile deionized water.
The MICs of epidermicin and vancomycin were determined by a modi-
fied 2-fold microtitre broth dilution method as described by Wu and
Hancock.12
Assessment of the toxicity of epidermicin
The toxicity of epidermicin was determined using repeated doses of
200 mg/kg into the larvae (which exceeded the MIC required for strain
ATCC 11195) at 0, 24 and 48 h. Two groups of 10 larvae were inoculated
in the last left proleg. Three negative control groups (10 larvae each) were
used in this experiment: one group that underwent no manipulation what-
soever, one group injected with PBS only (10 mL) and one group injected
with peptide suspension buffer only (10 mL). Test and control larvae were
stored in sterile Petri dishes in the dark at 378C for 120 h. Larvae were
inspected every 24 h and were considered dead if they did not move in re-
sponse to touch. The endpoint of the experiment was the death of all the
larvae in the experimental groups or the transition of larvae into pupae,
or the end of the experiment time (120 h).
Effect of epidermicin on haemocyte densities in
G. mellonella
Groups of six larvae were injected with peptide suspension buffer (control)
and another group with epidermicin at 10 mg/kg and were kept at 378C.
Haemocyte density was determined after 4 and 24 h. The haemolymph
of three larvae per treatment was collected in a pre-chilled 1 mL tube con-
taining a few granules of thiourea. Haemolymph was then diluted 1 in 10 in
cold PBS containing 0.37% (v/v) mercaptoethanol (Sigma-Aldrich). Haemo-
cytes were counted on a haemocytometer and their density in haemo-
lymph was calculated. No attempt was made to discriminate between
the different haemocyte subtypes.
Measuring bioavailability of epidermicin
Three groups of 30 larvae were injected with epidermicinatdoses of 2, 4 and
20 mg/larvae (equivalent to 10, 20 and 100 mg/kg, respectively) and kept at
378C. Three larvae of each group after 5, 10, 15, 20, 30, 40, 50, 60, 90 and
120 min were immersed in 70% alcohol and dried on sterile filter paper
before removing a thoracic leg of the larva using a sterile blade and the
haemolymph was collected in a pre-chilled 1 mL tube containing a few
grains of thiourea (Sigma-Aldrich) to prevent melanization. Three 2-fold
dilutions of the haemolymph were prepared and screening of the peptide
activity was carried out using an agar well diffusion method13 and S.
aureus strain ATCC 11195 as indicator.
Survival assay
S. aureus strain ATCC 11195 was grown in LB at 378C for 18 h and the optical
density at 600 nm (OD600) measured. The bacterial cells were then col-
lected and washed twice before being diluted with PBS so that 10 mL of
bacterial suspension contained 3×105–5×106 cfu (using previously
established cfu/mL counts). One group of 10 larvae per concentration
were inoculated in the last left proleg. Two negative control groups
(10 larvae each) were used in this and all following experiments: one
group underwent no manipulation, while the other group was injected
with PBS only. Test and control larvae were stored in Petri dishes in the
dark at 378C for 120 h and survival monitored as described above.
Protection from infection using vancomycin or epidermicin
Cells of S. aureus strains ATCC 11195 and the MRSA clinical isolate were
grown as described above before being washed twice using PBS. The
OD600 of the bacterial suspension was adjusted to 0.45 to give
2.5×108 cfu/mL and larvae injected in the last left proleg with 10 mL
(2.5×106/larva).
The viability of all larvae was confirmed 2 h post-inoculation. Then the
first treatment doses of vancomycin (1, 10 and 50 mg/kg), epidermicin (1,
10, 100 and 200 mg/kg) or PBS (control) were administered. Test and
control larvae were stored in Petri dishes in the dark at 378C for 120 h.
Repeat treatment doses of vancomycin, epidermicin or PBS were given at
24 and 48 h. Larvae were inspected every 24 h for 120 h.
Following initial experiments, the antistaphylococcal activity of epider-
micin was determined using a single dose of 1, 10 or 100 mg/kg adminis-
tered 0, 15, 30 or 60 min after inoculation with strain ATCC 11195.
Statistics
Survival analysis and statistical significance were determined using the
log-rank test and the Kaplan–Meier survival curves were plotted using
SPSS v.19.
Results and discussion
In the present study, G. mellonella wax moth larvae were used as a
non-mammalian model system to evaluate the activity of the
novel antistaphylococcal peptide epidermicin. The activity of bac-
teriocins has not previously been tested in this manner in G. mello-
nella. The G. mellonella model has been cited as a suitable
pre-screen for efficacy assessment of antistaphylococcal agents.3
Epidermicin NI01 is not toxic towards G. mellonella larvae
and has no effect on haemocyte densities
The MICs of epidermicin and vancomycin for S. aureus ATCC 11195
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The MIC of synthetic epidermicin is lower than we have previously
reported for natively synthesized peptide. Peptide suspension
buffer or epidermicin peptide administered at concentrations up
to 40 mg/larvae (200 mg/kg) did not result in death or visible
injury, indicating that the peptide was not toxic towards the
larvae. This supports our previous work,1 where we demonstrated
that epidermicin is not toxic towards murine fibroblasts at concen-
trations of up to 100 times the MIC and indicates that epidermicin
may have limited toxicity in mammalian systems.3,4
To investigate whether administration of epidermicin could
evoke an antimicrobial immune response independent of its anti-
microbial properties, the ability of epidermicin to alter the haemo-
cyte density was determined, since this is an indication of larval
susceptibility to infection. The peptide does not boost this particu-
lar element of the larval immune system, as no significant differ-
ences were observed between haemocyte density in the
peptide-treated (cell count of 296797+6292 at 24 h) and
control (304237+19105) groups (P¼0.55–0.98). It is possible
that the rate of phagocytosis may be increased by the peptide,
but we are confident that any efficacy against S. aureus is not
a manifestation of a simulation of G. mellonella antimicrobial
peptides.
Epidermicin has appreciable bioavailability in
G. mellonella larvae
To determine the bioavailability of the epidermicin after treating
the larvae, a bioactivity assay was performed using different con-
centrations of the peptide and different haemolymph collection
times. The haemolymph retained antistaphylococcal activity only
at an epidermicin dosage of 100 mg/kg and only if assayed at
,50 min post-administration (data not shown). This suggests
that the peptide is either being degraded or activity is being
limited by complex formation with constituents of the haemo-
lymph. The peptide is highly stable1 in vitro and further investiga-
tions are warranted to improve the bioavailability of epidermicin
in this model.
Epidermicin can protect G. mellonella larvae from
infection with MSSA and MRSA
The effect of S. aureus ATCC 11195 on the survival of the larvae
appeared to be dose dependent, where survival was reduced
with increasing inoculum of S. aureus. Although all inoculum
doses showed a reduction in larval survival, inoculum doses
ranging between 1.25×106 and 2.5×106 were selected for use in
further studies, as they showed significant differences in larval sur-
vival compared with the uninfected control group and a gradual re-
duction in survival rate covering the whole experiment period
(Figure 1). Vancomycin, even at a low concentration of 1 mg/kg,
showed a significant (P¼0.001) effect on larval survival compared
with the untreated control group (not shown).
In initial experiments, the highest concentration (200 mg/kg) of
epidermicin (administered 2 h post-infection) significantly
increased the survival of larvae infected with either MSSA strain
ATCC 11195 or the clinical MRSA strain compared with untreated
controls (Figures 2 and 3). The lower concentration (100 mg/kg),
which correlated to 100 times the MIC for strain ATCC 11195,
failed to achieve statistical significance under the standard




























Figure 2. Survival of G. mellonella larvae infected with S. aureus strain ATCC
1195 and treated with various doses of epidermicin 2 h post-infection.
Numbers in the graph represent the P value of each treatment compared





























Figure 1. Survival of G. mellonella larvae infected with different
concentrations of S. aureus strain ATCC 1195. Numbers in the graph
represent the P value of each treatment compared with the uninfected
control.
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epidermicin activity was only detectable up to 50 min post-
administration. More sensitive detection assays such as mass
spectrophotometric analysis of the haemolymph may confirm if
epidermicin is being degraded in the larvae.
In all assays, comparability to the control treatment of vanco-
mycin was not achieved. We do not consider this to be a significant
limitation, as vancomycin is a very effective antistaphylococcal
agent with proven efficacy in this model.4,14 In addition, this
work did not aim to demonstrate superiority over the current
standard treatment; we merely used vancomycin as a positive
control agent.
Numerous other factors could be responsible for the lack of pro-
nounced activity following therapy with epidermicin, including the
virulence of the strains used or the in vivo distribution and bioavail-
ability of the peptide. To further examine the antibacterial activity
of the peptide, a modified dosing regimen was developed using a
single dose of peptide at 100 mg/kg at different times post-
infection with MSSA strain ATCC 11195. This modified protocol
showed a significant association between time of treatment and
survival of the larvae, and treatments up to 30 min post-infection
significantly increased larval survival (Figure 4). Further investiga-
tions are required to examine what is underlying the reduced effi-
cacy of epidermicin administered outside the 30 min window.
Although the exact peptide–host interaction is not clear, our
data suggest that epidermicin has some pharmacokinetic limita-
tions that need to be identified and eliminated in order to
improve its effectiveness.
Conclusions
In conclusion, epidermicin does have in vivo antistaphylococcal ef-
ficacyand significantly improved the survival of G. mellonella larvae
infected with representative strains of MRSA and MSSA. While this
result is promising, it will be important to explore different
dosages and to determine whether similar results can be obtained
for other organisms, as epidermicin has potent activity against a
range of Gram-positive pathogens. Increasing the bioavailability
of the peptide is clearly also required. This is the first demonstration
of the in vivo efficacy of a peptide from the type IIc group of un-
modified bacteriocins, and the findings justify further development
of epidermicin towards potential therapeutic use. Use of a synthet-
ic peptide will expand the possibilities for rational development of
analogues with altered activity.
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Figure 3. Survival of G. mellonella larvae infected with a clinical MRSA strain
and treated with 200 mg/kg epidermicin at various times post-infection.
Numbers in the graph represent the P value of each treatment compared






























Figure 4. Survival of G. mellonella larvae infected with S. aureus strain ATCC
1195 and treated with 100 mg/kg epidermicin at various times
post-infection. Numbers in the graph represent the P value of each
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